Caraco Y - Search Results

1

Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults.

Muszkat M, Bialer O, Blotnick S, Adar L, Xie HG, Ufer M, Cascorbi I, Caraco Y. Muszkat M, et al. Among authors: caraco y. Clin Ther. 2010 Feb;32(2):347-56. doi: 10.1016/j.clinthera.2010.02.008. Clin Ther. 2010. PMID: 20206792 Clinical Trial.

2

Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.

Muszkat M, Blotnik S, Elami A, Krasilnikov I, Caraco Y. Muszkat M, et al. Among authors: caraco y. Clin Ther. 2007 Mar;29(3):427-37. doi: 10.1016/s0149-2918(07)80081-6. Clin Ther. 2007. PMID: 17577464 Clinical Trial.

3

Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.

Mlynarsky L, Bejarano-Achache I, Muszkat M, Caraco Y. Mlynarsky L, et al. Among authors: caraco y. Eur J Clin Pharmacol. 2012 May;68(5):617-27. doi: 10.1007/s00228-011-1143-z. Epub 2011 Nov 10. Eur J Clin Pharmacol. 2012. PMID: 22071881

4

Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study.

Bejarano-Achache I, Levy L, Mlynarsky L, Bialer M, Muszkat M, Caraco Y. Bejarano-Achache I, et al. Among authors: caraco y. Clin Ther. 2012 Apr;34(4):811-23. doi: 10.1016/j.clinthera.2012.02.009. Epub 2012 Mar 13. Clin Ther. 2012. PMID: 22417713

5

Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects.

Shaul C, Blotnick S, Muszkat M, Bialer M, Caraco Y. Shaul C, et al. Among authors: caraco y. Mol Diagn Ther. 2017 Feb;21(1):75-83. doi: 10.1007/s40291-016-0247-7. Mol Diagn Ther. 2017. PMID: 27878474

6

The impact of R353Q genetic polymorphism in coagulation factor VII on the initial anticoagulant effect exerted by warfarin.

Shaul C, Blotnick S, Deutsch L, Rosenberg G, Caraco Y. Shaul C, et al. Among authors: caraco y. Eur J Clin Pharmacol. 2019 Mar;75(3):343-350. doi: 10.1007/s00228-018-2594-2. Epub 2018 Nov 9. Eur J Clin Pharmacol. 2019. PMID: 30411147

7

Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance.

Shaul C, Blotnick S, Adar L, Muszkat M, Bialer M, Caraco Y. Shaul C, et al. Among authors: caraco y. Clin Pharmacokinet. 2022 Aug;61(8):1187-1198. doi: 10.1007/s40262-022-01141-2. Epub 2022 Jun 14. Clin Pharmacokinet. 2022. PMID: 35699912

8

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

Caraco Y, Blotnick S, Muszkat M. Caraco Y, et al. Clin Pharmacol Ther. 2008 Mar;83(3):460-70. doi: 10.1038/sj.clpt.6100316. Epub 2007 Sep 12. Clin Pharmacol Ther. 2008. PMID: 17851566 Clinical Trial.

9

Major bleeding caused by warfarin in a genetically susceptible patient.

Bloch A, Ben-Chetrit E, Muszkat M, Caraco Y. Bloch A, et al. Among authors: caraco y. Pharmacotherapy. 2002 Jan;22(1):97-101. doi: 10.1592/phco.22.1.97.33491. Pharmacotherapy. 2002. PMID: 11794436

10

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.

Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H. Takahashi H, et al. Among authors: caraco y. Clin Pharmacol Ther. 2003 Mar;73(3):253-63. doi: 10.1067/mcp.2003.26a. Clin Pharmacol Ther. 2003. PMID: 12621390

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters